Back to top

Nurix Therapeutics price target raised to $34 from $32 at Truist

Truist analyst Gregory Renza raised the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $32 and keeps a Buy rating on the shares after...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Nurix Therapeutics, Inc. (NRIX)

Roche Holding AG (RHHBY)

Rogers Corporation (ROG)

Roper Technologies, Inc. (ROP)